^
Chr t(15;17)
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
PML-RARA fusion
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
No biomarker
Acute Promyelocytic Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
No biomarker
Acute Promyelocytic Leukemia
cytarabine + daunorubicin
Sensitive: A2 - Guideline
STAT5b-RARA fusion
Acute Promyelocytic Leukemia
DCAG
Sensitive: C4 – Case Studies
PML-RARA fusion
Acute Promyelocytic Leukemia
cytarabine + idarubicin hydrochloride + tretinoin
Sensitive: C4 – Case Studies
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
Acute Promyelocytic Leukemia
cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea
Sensitive: C4 – Case Studies
ZBTB16-RARA fusion
Acute Promyelocytic Leukemia
chidamide
Sensitive: D – Preclinical
STAT5b-RARA fusion
Acute Promyelocytic Leukemia
chidamide
Sensitive: D – Preclinical
NPM-RARA fusion
Acute Promyelocytic Leukemia
chidamide
Sensitive: D – Preclinical